Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL20720662 | 0.94 | EHMT2 (0.52) | EHMT2 | |
| SCHEMBL19260654 | 0.92 | EHMT2 (0.59) | EHMT2SPIN1 | |
| SCHEMBL19260657 | 0.91 | EHMT2 (0.56) | EHMT2 | |
| SCHEMBL19260631 | 0.90 | EHMT2 (0.57) | EHMT2SPIN1 | |
| SCHEMBL19260638 | 0.89 | EHMT2 (0.63) | EHMT2SPIN1 | |
| SCHEMBL19260607 | 0.88 | EHMT2 (0.59) | EHMT2SPIN1 | |
| SCHEMBL19260579 | 0.88 | EHMT2 (0.58) | EHMT2SPIN1 | |
| SCHEMBL19260751 | 0.88 | EHMT2 (0.58) | EHMT2 | |
| SCHEMBL19260584 | 0.87 | EHMT2 (0.63) | EHMT2 | |
| SCHEMBL19260647 | 0.87 | EHMT2 (0.65) | EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | claimed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | claimed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | claimed |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | EHMT2 2/4885SPIN1 599/4885 |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EHMT2 2/4885SPIN1 342/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EHMT2 2/4885SPIN1 599/4885 |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | EHMT2 2/4885SPIN1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.